DnB Asset Management AS Has $9.54 Million Position in Bioverativ Inc (BIVV)

DnB Asset Management AS boosted its stake in shares of Bioverativ Inc (NASDAQ:BIVV) by 33.6% during the 4th quarter, HoldingsChannel reports. The firm owned 177,001 shares of the biotechnology company’s stock after buying an additional 44,551 shares during the quarter. DnB Asset Management AS’s holdings in Bioverativ were worth $9,544,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BIVV. Wells Fargo & Company MN purchased a new position in shares of Bioverativ in the third quarter valued at about $124,500,000. Woodford Investment Management Ltd purchased a new position in shares of Bioverativ in the third quarter valued at about $85,455,000. Jackson Square Partners LLC purchased a new position in shares of Bioverativ in the third quarter valued at about $99,336,000. Old Mutual Global Investors UK Ltd. purchased a new position in shares of Bioverativ in the third quarter valued at about $96,827,000. Finally, ValueAct Holdings L.P. purchased a new position in shares of Bioverativ in the third quarter valued at about $72,514,000. Institutional investors own 95.99% of the company’s stock.

Shares of Bioverativ Inc (NASDAQ BIVV) opened at $58.75 on Thursday. Bioverativ Inc has a twelve month low of $40.00 and a twelve month high of $64.41. The stock has a market capitalization of $6,360.00 and a PE ratio of 14.36.

Bioverativ (NASDAQ:BIVV) last issued its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.25. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The firm had revenue of $291.60 million for the quarter, compared to analysts’ expectations of $285.45 million. Bioverativ’s revenue for the quarter was up 27.2% compared to the same quarter last year. equities analysts predict that Bioverativ Inc will post 2.48 EPS for the current fiscal year.

Several brokerages have recently commented on BIVV. Zacks Investment Research downgraded Bioverativ from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. Morgan Stanley restated an “underweight” rating and issued a $47.00 price objective (up from $45.00) on shares of Bioverativ in a research report on Friday, October 6th. Piper Jaffray Companies restated an “overweight” rating and issued a $71.00 price objective on shares of Bioverativ in a research report on Monday, October 23rd. Royal Bank of Canada began coverage on Bioverativ in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $59.00 price objective on the stock. Finally, Argus upgraded Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price objective on the stock in a research report on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $60.47.

ILLEGAL ACTIVITY WARNING: “DnB Asset Management AS Has $9.54 Million Position in Bioverativ Inc (BIVV)” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2018/01/11/dnb-asset-management-as-has-9-54-million-position-in-bioverativ-inc-bivv.html.

Bioverativ Company Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

What are top analysts saying about Bioverativ? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bioverativ and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit